M. Yamamoto-Sugitani

发表

Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia.

M. Taniwaki, J. Kuroda, Y. Shimura, 2012, Current cancer drug targets.

Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia

T. Taki, M. Taniwaki, S. Horiike, 2011, Proceedings of the National Academy of Sciences.

8q24 amplified segments involve novel fusion genes between NSMCE2 and long noncoding RNAs in acute myelogenous leukemia

Taku Tsukamoto, Yosuke Matsumoto, Tsutomu Kobayashi, 2014, Journal of Hematology & Oncology.

Low ADAMTS-13 activity during hemorrhagic events with disseminated intravascular coagulation

M. Taniwaki, S. Horiike, J. Kuroda, 2013, International Journal of Hematology.

Deletion or methylation of CDKN2A/2B and PVT1 rearrangement occur frequently in highly aggressive B-cell lymphomas harboring 8q24 abnormality

T. Taki, M. Taniwaki, S. Horiike, 2013, Leukemia & lymphoma.

Transcriptional dysregulation of the deleted in colorectal carcinoma gene in multiple myeloma and monoclonal gammopathy of undetermined significance

Y. Okuno, T. Taki, M. Taniwaki, 2015, Genes, chromosomes & cancer.

Clinical manifestation of angioimmunoblastic T-cell lymphoma with exuberant plasmacytosis

M. Taniwaki, S. Horiike, J. Kuroda, 2013, International Journal of Hematology.

RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma

M. Taniwaki, S. Iida, Y. Shiotsu, 2012, Molecular Cancer Therapeutics.

Therapeutic Discovery RSK 2 Ser 227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma

M. Taniwaki, S. Iida, Y. Shiotsu, 2012 .

Suppression of SERPINA1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells.

M. Taniwaki, S. Horiike, J. Kuroda, 2014, Leukemia research.

Burkitt Lymphoma Preceded by Autoimmune Hemolytic Anemia due to Anti-D Antibody.

M. Taniwaki, S. Horiike, J. Kuroda, 2016, Internal medicine.

Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder

J. Kuroda, Y. Shimura, M. Yamamoto-Sugitani, 2021, Annals of Hematology.

Comprehensive cytogenetic study of primary cutaneous gamma-delta T-cell lymphoma by means of spectral karyotyping and genome-wide single nucleotide polymorphism array.

M. Taniwaki, S. Horiike, J. Kuroda, 2012, Cancer genetics.

Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy

M. Taniwaki, S. Horiike, J. Kuroda, 2015, Annals of Hematology.

High Frequencies of Drug-resistant Pathogens in Blood Stream Infections Associated with Hematologic Disorders: Five-year single institutional surveillance from 2010 to 2014

S. Horiike, J. Kuroda, Ommega Internationals, 2017 .

Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma

M. Taniwaki, S. Horiike, J. Kuroda, 2012, International Journal of Hematology.

Frequent PVT1 rearrangement and novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in multiple myeloma with 8q24 abnormality.

I. Hanamura, T. Taki, M. Taniwaki, 2012, Cancer research.

Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era

M. Taniwaki, S. Horiike, J. Kuroda, 2017, International Journal of Hematology.

Hematopoietic progenitor cell mobilization using low‐dose cyclophosphamide and granulocyte colony‐stimulating factor for multiple myeloma

M. Taniwaki, H. Kaneko, S. Horiike, 2013, Journal of clinical apheresis.

Chromosomal abnormality variation detected by G‐banding is associated with prognosis of diffuse large B‐cell lymphoma treated by R‐CHOP‐based therapy

M. Taniwaki, S. Horiike, J. Kuroda, 2018, Cancer medicine.

Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab.

M. Taniwaki, S. Horiike, J. Kuroda, 2012, Japanese journal of clinical oncology.

Cyclosporine A and reduced-intensity conditioning allogeneic stem cell transplantation for relapsed angioimmunoblastic T cell lymphoma with hemophagocytic syndrome.

M. Taniwaki, S. Horiike, J. Kuroda, 2012, Internal medicine.

FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors

M. Taniwaki, S. Horiike, J. Kuroda, 2013, Apoptosis.

Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.

M. Taniwaki, S. Iida, S. Horiike, 2014, Cancer research.